EVT.XETRA Evotec SE

Healthcare Pharmaceuticals XETRA Stock Exchange
3.09 EUR
Close of Nov 5, 2026
2.41 6.73
Market cap
EUR 549M
P/E
-
P/B
0.76x
ROE
-50.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is EVT.XETRA undervalued?

Graham number

The Graham number of Evotec SE cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Evotec SE fundamental analysis

No fundamental analysis for Evotec SE yet.

Evotec SE stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Evotec SE

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and…

Full company profile